---
schema_version: "secwatch.filing_event.v1"
accession: "0001999480-26-000016"
form_type: "8-K"
ticker: "ANRO"
cik: "0001999480"
company_name: "Alto Neuroscience, Inc."
filed_at: "2026-05-28T12:18:14+00:00"
generated_at: "2026-05-28T12:20:17.492172+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.5
calibrated_materiality_score: 0.5
confidence: "high"
source: SEC EDGAR
---

# Alto Neuroscience appoints Andrew Miller to board; former Karuna Therapeutics president

## Summary
- Andrew Miller, Ph.D., appointed to board effective May 27, 2026, filling vacancy after board size increased to seven.
- Miller founded Karuna Therapeutics and served as President of R&D until its acquisition by Bristol Myers Squibb in March 2024.
- Appointed to the Nominating and Corporate Governance Committee, replacing Christopher Nixon Cox.
- Initial option grant for up to 48,200 shares (Black-Scholes value ≤$400k); annual retainer $40k plus $5k for NCGC service.
- Board determined Miller is independent under NYSE and SEC rules.

## SEC filing metadata
- accession: 0001999480-26-000016
- form_type: 8-K
- ticker: ANRO
- cik: 0001999480
- company_name: Alto Neuroscience, Inc.
- filed_at: 2026-05-28T12:18:14+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.5
- calibrated_materiality_score: 0.5
- confidence: high
- sec_items: 5.02
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/0001999480-26-000016-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/alto-20260527.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001999480-26-000016
- JSON: https://secwatch.observer/filing/0001999480-26-000016.json
- Plain text: https://secwatch.observer/filing/0001999480-26-000016.txt

## Source-grounded claims
- claim_id: c5d0d5e62f
  claim: Andrew Miller was appointed as Director at Alto Neuroscience, Inc..
  evidence_excerpt: the Board of Directors (the “Board”) of Alto Neuroscience, Inc. (the “Company”), following the recommendation of the Board’s Nominating and Corporate Governance Committee (the “NCGC”), unanimously appointed Andrew Miller, Ph.D. to serve as a member of the Board.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1999480/000199948026000016/0001999480-26-000016-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.